Month: February 2026

2025 Full year results Resilient results and strong cash flow supported by cost management and restructuring FCF1 of €314m n Proposed dividend of €1.95 n Ongoing €200m share buyback Bekaert delivered a resilient performance in 2025. The year was marked by shifts in global trade policies which created uncertainty and undermined demand. In addition, slower growth in the hydrogen end market required adjustment to bring footprint in line with demand outlook. At the same time, Bekaert has translated robust demand from investments in power and data transmission networks into increased sales and order books. Within these mixed global market dynamics, sales volumes remained flat versus 2024, while pass-through of lower input costs, currency and mix impacts and the strategic exit of lower margin business in Latin America reduced sales. Cost savings...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026. Details of the events: TD Cowen 46th Annual Health Care ConferenceBoston, MA, March 2-4, 2026Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 2 at 2.30-3.00 pm ET (8.30-9.00 pm CET). Leerink Partners Global Healthcare Conference 2026Miami, FL, March 9-11 March, 2026Molecular Partners CEO Patrick Amstutz will...

Press Release dsm-firmenich cancels its shares following completion of its €1.08 billion share repurchase program Kaiseraugst (Switzerland), Maastricht (Netherlands), February 26 2026 dsm-firmenich, innovators in nutrition, health, and beauty, announces that following the completion of its €1.08 billion share buyback program in 2025, the company has cancelled 12,049,441 shares. As a result, the total number of issued shares has been reduced by approximately 4.5%, from 265,676,388 to 253,626,947 shares. For more information, please contact: dsm-firmenich investor relations enquiries:Email: investors@dsm-firmenich.com dsm-firmenich media enquiries:Email: media@dsm-firmenich.com    About dsm-firmenichAs innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances...

Corbion, the Amsterdam-listed sustainable food-ingredients company that champions preservation through application of science, today publishes its results for the year ending 31 December 2025.Key highlights annual results 2025:   Organic sales growth: +2.2% (Q4: +5.4%) Volume/mix: +3.4% (Q4: +8.8%) Price:           -1.2% (Q4: -3.4%) Sales: € 1,267.4 million (Q4: € 310.2 million) Adjusted EBITDA: € 204.3 million   (Q4: € 48.0 million)Adjusted EBITDA organic growth of +26.7%  Operating profit: € 116.5 million, an organic increase of +66.1%  Cash flow from operating activities: € 160.9 million  Free Cash Flow: € 90.8 million  EPS increased +63.3% to €1.29 Proposal to distribute a dividend of €1.00 per share consisting of a regular dividend of € 0.64...

On February 25, 2026, the fund’s subsidiary EfTEN Ermi OÜ and Tartu Südamekodu OÜ reached an agreement on the expansion of the elderly care home located at Ermi tn 13, Tila village, Tartu municipality, Tartu County. As a result, 72 additional beds will be added.  The “Tartu Südamekodu” elderly care home, developed through the parties’ previous cooperation, has been providing services to clients since August 2024 and currently comprises 180 beds. By the end of last year, the facility had reached full occupancy.  It is planned to apply for a building permit for the construction of the extension in the second quarter of 2026 and then conduct a construction procurement, with the aim of completing the extension by June 2027. Tartu Südamekodu will then rent out the entire part of the building under construction. The estimated cost of the extension...

Highlights Record results withGroup turnover at 4.2 billion euros compared to 4.1 billion euros a year ago EBITDA at 931 million euros from 764 million euros a year ago, an increase of 22%, and reaching 22.4% of turnover, up from 18.6% for 2024 Net profit reaching 346 million euros, compared to 288 million euros a year ago, an increase of 20% Proposed gross dividend of 4.5 euros per share, compared to 3.8 euros per share a year agoOrder book stood at 7.6 billion euros at the end of the year, above both mid-year and 3Q25 levels and down from 8.2 billion euros a year ago Following the acquisition of Havfram, DEME has taken delivery of two next-generation offshore installation vessels, Norse Wind and Norse Energi, with project work commencing in 2026 DEME to celebrate its 150th anniversary in 2026Attachment...

Strong 2025 performance with renewedcommercial momentum at year-endRevenue up +10.3% in constant currencies, led by +14.4% growth in constant currencies of Planisware’s SaaS Model Commercial momentum improving and strong bookings with new logos at year-end Adjusted EBITDA margin* up +220bps to 37.4% of revenue reflecting operational discipline and scalability Profit for the period up +17.0% year-on-year to € 50.0 million or € 0.71 earnings per share Strong cash generation with adjusted FCF* reaching € 59.3 million (80.1% cash conversion), reinforcing the sound net cash position* reaching € 195.6 million € 0.36 proposed dividend per share, +16.1% year-on-year, representing a 50% pay-out 2026 objectives:Low double-digit revenue growth in constant currencies c. 37% Adjusted EBITDA margin1 c. 80% Cash Conversion Rate*Paris, France,...

Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MGResults support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMGRegulated Information – Inside Information  February 26, 2026, 6:30 AM CET    Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronidase-qvfc) in adults with ocular myasthenia gravis (oMG). ADAPT OCULUS met its primary endpoint (p-value=0.012), showing that patients living...

Ad hoc announcement pursuant to Article 53 LR26 February 2026 – 06:30 AMThe Feintool Group’s business performance in the 2025 financial year reflects a market environment that remains challenging, with differing dynamics across regions and technologies. The global automotive market is growing at a low single-digit rate, while shifts in climate policy and subsidy schemes – particularly in the United States – are influencing investment decisions and the pace of electrification. At the same time, demand for industrial applications has remained subdued. Against this backdrop, Feintool has continued to align its cost structure consistently with prevailing market conditions, while maintaining a high degree of operational flexibility and a solid financial base. This enables the Group to remain a reliable and well-established partner for its customers,...